Supplementary material

Supplementary Table 1: Demographic, clinical, laboratory, technical and treatment data for investigated patients. TLC= total lung capacity, DLCO= diffusion capacity for carbon monoxide.

	PRE-HSCT PATIENT 1	PATIENT 2
GENETIC		
ITPR3 VARIANT	c.5549G>A; p.Arg1850GIn c.7570C>T; p.Arg2524Cys	c.4882T>C; p.Phe1628Leu c.5549G>A; p.Arg1850GIn
CLINICAL SPECTRUM AND LA	BORATORY FINDINGS	
HEMATOPOIETIC	T ⁻ B ⁻ NK ⁺ CID	ITP AIHA
LYMPHOPROLIFERATION		GLILD
GASTROINTESTINAL	Enteropathy	Enteropathy Chronic gastritis
INFECTIONS	Bronchopneumonia (chronic colonization with <i>H. influenzae</i> , <i>P. aeruginosa</i> , <i>S. aureus</i>) Suspected mycobacterial disease (granulomatous airway infection) Multiple viral infections (RSV, Molluscum contagiosum, Parainfluenza virus,)	Bronchopneumonia (<i>H. influenzae, M. pneumoniae</i>) Recurrent URTI Invasive pulmonary aspergillosis Gastrointestinal (<i>Blastocystis hominis</i>) Primo CMV infection
OTHER	Brittle hair Delayed dentition, conical teeth Peripheral neuropathy	
LABORATORY EXAMINATIONS	Elevated IgG Absent pneumococcal vaccine response	Low IgG Low switched memory B cells Absent pneumococcal vaccine response
TECHNICAL EXAMINATIONS		
CT SCAN	Consolidation zones Bronchiectasis	GLILD , aspergillus related lesions
PULMONARY FUNCTION TEST	Obstructive	Mild restrictive (TLC 83% predicted value) and decreased diffusion capacity (DLCO 73% predicted value)
ABDOMINAL ULTRASOUND	Cholecystolithiasis	Normal (post splenectomy)
TRANSTHORACAL ECHOCARDIOGRAPHY	Normal	NA
BIOPSY		Lung: lymphoplasmocytic infiltrate Stomach: chronic gastritis. Helicobacter pylori negative.
IMMUNOMODULATORY TREAT	MENT (INDICATION)	
CORTICOSTEROIDS		Prednisone (ITP, AIHA)
ANTI-CD20		Rituximab (AIHA)
IVIG/SCIG	SCIG	IVIG
OTHER		Cyclosporin (AIHA) Cyclophosphamide (AIHA)

Supplementary Table 2: Laboratory values of P1 at different relevant time points. Values out of range are italicized. ND=not-detectable. *corticosteroid treatment.

	REFERENCE	LAST FOLLOW UP 6 YEARS POST -HSCT	REFERENCE	CONTROL BEFORE HSCT	RESPIRATORY EXACERBATION	ONSET OF LYMPHOPENIA, RSV INFECTION
COMPLET						
HEMOGLOBIN	13.0-16.0 g/dL	13.3	11.0-13.5 g/dL 11.5-13.5 g/dL	10.3	10.8	9.9
THROMBOCYTES	150-450x10 ⁹ /L	193	150-450x10 ⁹ /L	243	393	233
TOTAL LEUKOCYTES	4.5-13 x10 ⁹ /L	3.98	5.5-15.5x10 ⁹ /L 6-17.5x10 ⁹ /L	3.64	5.46	4.51
LYMPHOCYTES	2.0-8.0x10 ⁹ /L	1.7	4.0-13.5x10 ⁹ /L 2.0-8.0x10 ⁹ /L	1.3	1.9	0.4
IMMUNOGLOBULINS						
IGG	5.76-12.65 g/L	13.80	3.54-9.34 g/L 5.58-12.54 a/L	19.4	ND	13.7
IGA	0.81-2.32 g/L	<0.07	0.14-0.86 q/L		ND	2.95
IGM	0.30-1.59 g/L	0.33	0.29-1.39 g/L		ND	0.41
LYMPHOCYTE COUNTS	5					
B CELLS (CD19⁺)	200-600/mm3	248	600-2700/mm ³ 200-2100/mm ³	92	ND	301
SWITCHED B MEMORY (CD27 ⁺ IGM ⁻ IGD ⁻)	% of CD19⁺ B cells	2.8	% of CD19⁺ B cells		ND	ND
T CELLS (CD3⁺)	800-3500/mm ³	1408	1600-6700/mm ³ 900-4500/mm ³	995	ND	182
CD4⁺ T CELLS	400-2100/mm ³	849	1000-4600/mm ³ 500-2400/mm ³	217	ND	ND
CD8⁺ T CELLS	200-1200/mm ³	466	400-2100/mm ³ 300-1600/mm ³	774	ND	ND
NAÏVE T CELLS (CD27 ⁺ CD45RA ⁺)			% of CD3			
NK CELLS	70-1200/mm ³	72	200-1200/mm ³ 100-1000/mm ³		ND	ND
LYMPHOCYTE STIMULA	TION					
PHA	≥5 x10³ cpm	30.48	≥5 x10³ cpm		280.71	ND
CANDIDA	≥5 x10 ³ cpm		≥5 x10 ³ cpm		8.73	ND
TETANUS TOXOID	≥5 x10³ cpm		≥5 x10³ cpm		0.96	ND
VACCINATION RESPONS	SE					
HEPATITIS B SURFACE AS			>=10 IU/L		ND	0
POLIOMYELITISVIRUS TYPE 1 AS TYPE 2 AS TYPE 3 AS			>= 1/8		ND	1/4 1/32 1/128

Supplementary Table 3: Laboratory values of P2 at different relevant time points. Values out of range are italicized. NA=non-applicable, ND=not-detectable. *corticosteroid treatment.

	REFERENCE	LAST FOLLOW UP	HOSPITALIZATION BRONCHO- PNEUMONIA	HOSPITALIZATION PRIMO CMV INFECTION	DIAGNOSIS CVID	START IVIG	RE-ADMISSION AIHA*	INITIAL PRESENTATION ITP
COMPLETE								
HEMOGLOBIN	12-18 g/dL	16.9	17.1	14.6	16.8	14	2.6	15.9
THROMBOCYTES	150-450x10 ⁹ /L	305	450	262	352	425	198	9
LEUKOCYTES	4-10x10 ⁹ /L	14.69	19.6	17.64	10.32	13.4	84.8	6.7
IMMUNOGLOBULINS								
IGG	7.51-15.6 g/L	13.4	18.7	8.92	14	6.83	22.2	9.42
IGA	0.82-4.53 g/L	4.89	3.9	3.10	3.41	NA	1.61	1.73
IGM	0.46-3.04 g/L	1.64	0.92	0.43	0.44	NA	0.5	0.25
LYMPHOCYTE COUNT	rs							
B CELLS (CD19⁺)	82-476/µL	NA	429	NA	250	352	NA	NA
SWITCHED B MEMORY (CD27 ⁺ IGM ⁻ IGD ⁻)	% of CD19 ⁺ B cells	NA	NA	NA	ND	1.1	NA	NA
T CELLS (CD3 ⁺)	798-2823/µL	NA	2056	NA	602	1385	3512	NA
CD4⁺ T CELLS	455-1885/µL	NA	517	NA	418	920	2149	NA
CD8⁺ T CELLS	219-1124/µL	NA	1461	NA	157	NA	1219	NA
LYMPHOCYTE STIMU	LATION							
PHA	≥5 [x10 ³] cpm	NA	NA	NA	1640.91	NA	NA	NA
CANDIDA	≥5 [x10 ³] cpm	NA	NA	NA	191.14	NA	NA	NA

Supplementary Table 4: Protein-coding variants in *ITPR3* are predicted to be

damaging. Gene-specific Mutation Significance cut-off (MSC) for the CADD score is 5.7. CADD: Combined Annotation Dependent Depletion. SIFT: Sorting Intolerant From Tolerant.

variant	CADD	SIFT	DANN
p.Phe1628Leu	25.8	damaging	damaging
p.Arg1850Gln	19.9	tolerated	damaging
p.Arg2524Cys	32.0	damaging	damaging

Supplementary Table 5: Primers for Sanger sequencing of identified variants.

variant	FW primer (5' \rightarrow 3')	RV primer (5' \rightarrow 3')
p.Phe1628Leu	CAGACATCACGCTGTGTTCAGGG	CTCCGACTCCATGAGGTCTTG
p.Arg1850Gln	CAACATGAATGACCTGGGCAGCC	CTGGGAAGCACGATCTTGTGTG
p.Arg2524Cys	CTGGGTCCTCAATATCACAGCCC	GGCTCATGTCCTCACCTAGAAACC

Supplementary Table 6: Primers used for subunit-specific qPCR analysis.

	FW primer (5' \rightarrow 3')
ITPR1	CTCAACAAACTGCACCACGC
ITPR2	TTCATCATGACCCATGCCGT
ITPR3	GCACCTTCATCCGGGGCTATAAG

RV primer $(5' \rightarrow 3')$ AGGAGCTGGATCACATTGCC TCAGGATTAAGCTCTGCAGCTA CGGTAGATGAGGTCAAAGAGCAGG **Supplementary Table 7: Primers used for cloning.** Base changes to introduce the desired mutation are underlined.

	FW primer (5' \rightarrow 3')	RV primer (5' \rightarrow 3')
subcloning	CAGACGATTGTGGTGCAGCTG	CTTTGGTGGTGGGGTCGACT
F1628L		
subcloning	AGTCGACCCCACCACCAAAG	CACCTCCGAGTTCTCACGCTCTTC
R1850Q		
subcloning	GGTGCCCTCAATCTGACCAACAAG	GCAACTAGAAGGCACAGTCGAGG
R2524C		
mutagenesis	CTGGCCTGAGCTGCTC <u>C</u> TCCTGG	CACTGCCCTCCAGGA <u>G</u> GAGCAGCTCAG
F1628L	AGGGCAGTG	GCCAG
mutagenesis	CAGCCTGCGCC <u>A</u> GGGGCACGAGG	CTCACCTCGTGCCCC <u>T</u> GGCGCAGGCTG
R1850Q	TGAG	
mutagenesis	CATCTTTGGGGTAATCATCGACAC	CTGCTTCTCACTAC <u>A</u> CAGGTCAGCGAA
R2524C	CTTCGCTGACCTG <u>T</u> GTAGTGAGAA	GGTGTCGATGATTACCCCAAAGATG
	GCAG	

Supplementary Figure 1: Identified variants in *ITPR3* are highly conserved. (A)

Sequencing results for the variants identified in the two kindreds. The relevant base is marked in red and alternative bases and amino acids indicated below the reference. **(B)** Conservation of the relevant residues in *ITPR3* across species. **(C)** Conservation of the relevant residues within the IP₃R family in humans. **(D)** View of the IP₃R3 channel pore structure in the plane of the R2524 amino acid. Illustration of the positively charged amino acid side chain of R2524 on the left (blue) and how it shields the negative charge of amino acid side chains of D2522 and D2518 (red). Location of the side chains in the case of the C2524 variant with its neutral side chain (cyan).



2507 GVIIDTFADLRSEKQKKEEIL 2527

G.gallus

F1628L

R3	1618	VDVLHWPELLFLEGSEAYQRC	1638	
R1	1636	VDVLHRPELL FPENTDARRKC	1656	
R2	1629	VDVLYSPELLFPEGSDARIRC	1649	
		R1850Q		
R3	1842	YSLGPSLRRGHEVSERVQS	1860	
R1	1946	DHYQPGEGTQATADKAKDD	1964	
R2	1890	DIMCTGPEAGNTEEKSAEE	1908	
		R2524C		

IP3R3 2514 GVIIDTFADLRSEKQKKEEIL 2534 IP3R1 2595 GVIIDTFADLRSEKQKKEEIL 2615 IP3R2 2538 GVIIDTFADLRSEKQKKEEIL 2558



Supplementary Figure 2: Western Blot analysis of IP₃**R2 and total IP**₃**R expression is not reliably quantifiable. (A)** Western Blot analysis of IP₃R2 protein expression was performed using a subtype-specific antibody as well as a non-specific antibody (pan-IP₃R). Representative blots are shown for fibroblasts and **(B)** PBMCs indicating low IP₃R2 expression.



Supplementary Figure 3: Reconstitution of HEK-3KO cells with mutated IP₃R3 results in stable protein expression and reveals impaired channel function. (A)

Immunocytochemistry for IP₃R3 (green) was performed to validate physiological localization in HEK-3KO cell lines expressing either exogenous wild-type IP₃R3 (top) or mutant IP₃R3 (bottom). Representative images are shown. Red scale bars, 5 μ m. **(B)** Exogenous wild-type IP₃R3 and mutant IP₃R3 stable cell lines were western blotted alongside HEK293-3KO and HEK293 cell lines modified to express only endogenous wild-type IP₃R3 (endogenous IP₃R3). Representative blots are shown. **(C)** HEK-3KO cell lines stably transduced with the wild-type (exogenous) or mutated versions of the IP₃R3 receptor were stimulated with different concentrations of the GPCR agonist Carbachol in Ca²⁺ imaging buffer. Cells only expressing endogenous IP₃R3 (endogenous) and HEK-3KO cells were used as controls. Representative traces of one well stimulated with 100 μ M CCH are shown for F1628L, **(D)** R1850Q or **(E)** R2524C as 340/380 ratio normalized to the first 5 values of the measurement. **(F)** Dose-response curves of the peak amplitude of representative cell lines stably expressing IP₃R3 with the F1628L (n=3), **(G)** R1850Q (n=3) or **(H)** R2524C (n=3) variant at different concentrations of Carbachol (CCH) are shown as mean ± SEM.



Supplementary Figure 4: Defective TCR-induced T cell proliferation in individuals from

kindred 2. PBMCs were labelled with the CFSE cell proliferation dye and stimulated with 10 μ g/mL plate-bound anti-CD3 and 5 μ g/mL soluble anti-CD28 for 3 and 4 days. **(A)** Total cell numbers in unstimulated or stimulated wells after 3 and **(B)** 4 days. The mean number of proliferations of cells that divided at least once (Proliferation Index), was calculated for **(C)** CD4⁺, **(D)** CD8⁺ and **(E)** CD19⁺ subsets. HD n=9, FL^{+/-} n=3, RQ^{+/-} n=3, P2 n=5. **(F)** Stimulation was performed with 5 μ g/mL soluble anti-CD3 and 5 μ g/mL soluble anti-CD28. The Proliferation Index for HD n=2, FL^{+/-} n=1, RQ^{+/-} n=1, P2 n=3 is shown for CD4⁺ T cells, **(G)** CD8⁺ T cells and **(H)** B cells Values are represented as mean + SEM. One-way ANOVA with multiple comparisons.

